Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia

Human Molecular Genetics

Volumn 24, Issue 12, 2015, Pages 3557-3570

  Malik, Manasi ^a   Chiles, Joe ^a   Xi, Hualin S ^b   Medway, Christopher ^c   Simpson, James ^a   Potluri, Shobha ^b   Howard, Dianna ^a   Liang, Ying ^a   Paumi, Christian M ^a   Mukherjee, Shubhabrata ^d   Crane, Paul ^d   Younkin, Steven ^c   Fardo, David W ^a   Estus, Steven ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b PFIZER INC   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CELL SURFACE RECEPTOR; CYCLIN T1; CYCLOHEXIMIDE; DACTINOMYCIN; INITIATION FACTOR 3; INITIATION FACTOR 4G; LINTUZUMAB; MESSENGER RNA; POLYADENYLIC ACID BINDING PROTEIN; CD33 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; ALLELE; ALZHEIMER DISEASE; ANTIGEN EXPRESSION; ARTICLE; CANCER GENETICS; CANCER PATIENT; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; EXON; EXON SKIPPING; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; INTERNALIZATION; INTRON; K562 CELL LINE; LEUKOCYTE; MALE; MONOCYTE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RNA SEQUENCE; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; U937 CELL LINE; ACUTE MYELOID LEUKEMIA; ALTERNATIVE RNA SPLICING; ANTAGONISTS AND INHIBITORS; CELL LINE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; RNA STABILITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLELES; ALTERNATIVE SPLICING; ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE; EXONS; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTRONS; LEUKEMIA, MYELOID, ACUTE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA STABILITY; RNA, MESSENGER; SIALIC ACID BINDING IG-LIKE LECTIN 3;

EID: 84930442437     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv092     Document Type: Article

References (47)

1. Lamba, J.K., Pounds, S., Cao, X., Downing, J.R., Campana, D., Ribeiro, R.C., Pui, C.H. and Rubnitz, J.E. (2009) Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. Leukemia, 23, 402-404.
2. Mortland, L., Alonzo, T.A., Walter, R.B., Gerbing, R.B., Mitra, A.K., Pollard, J.A., Loken, M.R., Hirsch, B., Raimondi, S., Franklin, J. et al. (2013) Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumabozogamicin-containing chemotherapy. Clin. Cancer Res., 19, 1620-1627.
3. Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., Jun, G., Destefano, A.L., Bis, J.C., Beecham, G.W. et al. (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet., 45, 1452-1458.
4. Naj, A.C., Jun, G., Beecham, G.W.,Wang, L.S., Vardarajan, B.N., Buros, J., Gallins, P.J., Buxbaum, J.D., Jarvik, G.P., Crane, P.K. et al. (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet., 43, 436-441.
5. Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J.C., Carrasquillo, M.M., Abraham, R., Hamshere, M.L., Pahwa, J.S., Moskvina, V. et al. (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet., 43, 429-435.
6. Carrasquillo, M.M., Belbin, O., Hunter, T.A., Ma, L., Bisceglio, G.D., Zou, F., Crook, J.E., Pankratz, V.S., Sando, S.B., Aasly, J.O. et al. (2011) Replication of EPHA1 and CD33 associations with late-onset Alzheimer's disease: a multi-centre casecontrol study. Mol. Neurodegener., 6, 54.
7. Malik, M., Simpson, J.F., Parikh, I., Wilfred, B.R., Fardo, D.W., Nelson, P.T. and Estus, S. (2013) CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing. J. Neurosci., 33, 13320-13325.
8. Raj, T., Ryan, K.J., Replogle, J.M., Chibnik, L.B., Rosenkrantz, L., Tang, A., Rothamel, K., Stranger, B.E., Bennett, D.A., Evans, D.A. et al. (2014) CD33: increased inclusion of exon 2 implicates the IgV-set domain in Alzheimer's disease susceptibility. Hum. Mol. Genet., 23, 2729-2736.
9. Crocker, P.R., Vinson, M., Kelm, S. and Drickamer, K. (1999) Molecular analysis of sialoside binding to sialoadhesin by NMR and site-directed mutagenesis. Biochem. J., 341, 355-361.
10. Hernandez-Caselles, T., Martinez-Esparza, M., Perez-Oliva, A.B., Quintanilla-Cecconi, A.M., Garcia-Alonso, A., Alvarez-Lopez, D.M. and Garcia-Penarrubia, P. (2006) A study of CD33 (siglec-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J. Leukoc. Biol., 79, 46-58.
11. Griciuc, A., Serrano-Pozo, A., Parrado, A.R., Lesinski, A.N., Asselin, C.N., Mullin, K., Hooli, B., Choi, S.H., Hyman, B.T. and Tanzi, R.E. (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron, 78, 631-643.
12. Dowell, J.A., Korth-Bradley, J., Liu, H., King, S.P. and Berger, M.S. (2001) Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J. Clin. Pharmacol., 41, 1206-1214.
13. Jurcic, J.G. (2012) What happened to anti-CD33 therapy for acute myeloid leukemia? Curr. Hematol. Malig. Rep., 7, 65-73.
14. Laszlo, G.S., Estey, E.H. and Walter, R.B. (2014) The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev, 28, 143-153.
15. Silva, A.L. and Romao, L. (2009) The mammalian nonsensemediated mRNA decay pathway: to decay or not to decay! Which players make the decision? FEBS Lett., 583, 499-505.
16. Urano, E., Miyauchi, K., Ichikawa, R., Futahashi, Y. and Komano, J. (2012) Regulation of cyclin T1 expression and function by an alternative splice variant that skips exon 7 and contains a premature termination codon. Gene, 505, 1-58.
17. Inacio, A., Silva, A.L., Pinto, J., Ji, X., Morgado, A., Almeida, F., Faustino, P., Lavinha, J., Liebhaber, S.A. and Romao, L. (2004) Nonsense mutations in close proximity to the initiation codon fail to trigger full nonsense-mediated mRNA decay. J. Biol. Chem., 279, 32170-32180.
18. Peixeiro, I., Inacio, A., Barbosa, C., Silva, A.L., Liebhaber, S.A. and Romao, L. (2012) Interaction of PABPC1 with the translation initiation complex is critical to the NMD resistance of AUG-proximal nonsense mutations. Nucleic Acids Res., 40, 1160-1173.
19. Neu-Yilik, G., Amthor, B., Gehring, N.H., Bahri, S., Paidassi, H., Hentze, M.W. and Kulozik, A.E. (2011) Mechanism of escape from nonsense-mediated mRNA decay of human beta-globin transcripts with nonsense mutations in the first exon. RNA, 17, 843-854.
20. Albanell, J., Codony, J., Rovira, A., Mellado, B. and Gascon, P. (2003) Mechanism of action of anti-HER2 monoclonal antibodies:scientific update on trastuzumab and 2c4. Adv. Exp. Med. Biol., 532, 253-268.
21. Walter, R.B., Raden, B.W., Zeng, R., Hausermann, P., Bernstein, I.D. and Cooper, J.A. (2008) ITIM-dependent endocytosis of CD33-related siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, SHP1 and SHP2. J. Leukocyte Biol., 83, 200-211.
22. Perez-Oliva, A.B., Martinez-Esparza, M., Vicente-Fernandez, J.J., Corral-San Miguel, R., Garcia-Penarrubia, P. and Hernandez-Caselles, T. (2011) Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells. Glycobiology, 21, 757-770.
23. Liu, M.Y. and Wu, M.C. (1992) Induction of human monocyte cell line U937 differentiation and CSF-1 production by phorbol ester. Exp. Hematol., 20, 974-979.
24. Legrand, O., Perrot, J.Y., Baudard, M., Cordier, A., Lautier, R., Simonin, G., Zittoun, R., Casadevall, N. and Marie, J.P. (2000) The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood, 96, 870-877.
25. Liu, Y., Walter, S., Stagi, M., Cherny, D., Letiembre, M., Schulz-Schaeffer, W., Heine, H., Penke, B., Neumann, H. and Fassbender, K. (2005) LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain, 128, 1778-1789.
26. Reed-Geaghan, E.G., Savage, J.C., Hise, A.G. and Landreth, G.E. (2009) CD14 and Toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J. Neurosci., 29, 11982-11992.
27. Ishida, A., Akita, K., Mori, Y., Tanida, S., Toda, M., Inoue, M. and Nakada, H. (2014) Negative regulation of Toll-like receptor-4 signaling through the binding of glycosylphosphatidylinositol-anchored glycoprotein, CD14, with the sialic acid-binding lectin, CD33. J. Biol. Chem., 289, 25341-25350.
28. Linnartz, B. and Neumann, H. (2013) Microglial activatory (immunoreceptor tyrosine-based activation motif )-and inhibitory (immunoreceptor tyrosine-based inhibition motif)-signaling receptors for recognition of the neuronal glycocalyx. Glia, 61, 37-46.
29. Linnartz, B.,Wang,Y. andNeumann,H. (2010) Microglialimmunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation. Int. J. Alzheimers Dis., 2010, 1-7.
30. Bradshaw, E.M., Chibnik, L.B., Keenan, B.T.,Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L.L., Imboywa, S., Lee, M., Von Korff, A. et al. (2013) CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat. Neurosci., 16, 848-850.
31. Caron, P.C., Dumont, L. and Scheinberg, D.A. (1998) Supersaturating infusional humanized anti-CD33 monoclonal antibody HUM195 in myelogenous leukemia. Clin. Cancer Res., 4, 1421-1428.
32. Levites, Y., Smithson, L.A., Price, R.W., Dakin, R.S., Yuan, B., Sierks, M.R., Kim, J., McGowan, E., Reed, D.K., Rosenberry, T.L. et al. (2006) Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J., 20, 2576-2578.
33. Caron, P.C., Jurcic, J.G., Scott, A.M., Finn, R.D., Divgi, C.R., Graham, M.C., Jureidini, I.M., Sgouros, G., Tyson, D., Old, L.J. et al. (1994) A Phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood, 83, 1760-1768.
34. Pollard, J.A.,Alonzo, T.A., Loken,M.,Gerbing, R.B.,Ho, P.A.,Bernstein, I.D., Raimondi, S.C., Hirsch, B., Franklin, J., Walter, R.B. et al. (2012) Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhoodAML. Blood, 119, 3705-3711.
35. Mingari, M.C., Vitale, C., Romagnani, C., Falco, M. and Moretta, L. (2001) Regulation of myeloid cell proliferation and survival by p75/AIRM1 and CD33 surface receptors. Adv. Exp. Med. Biol., 495, 55-61.
36. Mingari, M.C., Vitale, C., Romagnani, C., Falco, M. and Moretta, L. (2001) P75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells. Immunol. Rev., 181, 260-268.
37. Sutherland, M.K., Yu, C., Lewis, T.S., Miyamoto, J.B., Morris-Tilden, C.A., Jonas, M., Sutherland, J., Nesterova, A., Gerber, H.P., Sievers, E.L. et al. (2009) Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs, 1, 481-490.
38. Ling, I.F., Bhongsatiern, J., Simpson, J.F., Fardo, D.W. and Estus, S. (2012) Genetics of clusterin isoform expression and Alzheimer's disease risk. PLoS ONE, 7, e33923.
39. Zou, F., Gopalraj, R.K., Lok, J., Zhu, H., Ling, I.F., Simpson, J.F., Tucker, H.M., Kelly, J.F., Younkin, S.G., Dickson, D.W. et al. (2008) Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease. Hum. Mol. Genet., 17, 929-935.
40. Nelson, P.T., Braak, H. and Markesbery, W.R. (2009) Neuropathology and cognitive impairment in Alzheimer disease:a complex but coherent relationship. J. Neuropathol. Exp. Neurol., 68, 1-14.
41. Griffin, J.D., Linch, D., Sabbath, K., Larcom, P. and Schlossman, S.F. (1984) A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leukemia Res., 8, 521-534.
42. Zhang, X., Ding, L. and Sandford, A.J. (2005) Selection of reference genes for gene expression studies in human neutrophils by real-time PCR. BMC Mol. Biol., 6, 4.
43. Cancer Genome Atlas Research, N. (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med., 368, 2059-2074.
44. Grubbs, F.E. (1950) Sample criteria for testing outlying observations. Ann. Math. Stat., 21, 27-58.
45. Ridge, P.G., Mukherjee, S., Crane, P.K. and Kauwe, J.S. and Alzheimer's Disease Genetics, C. (2013) Alzheimer's disease:analyzing the missing heritability. PLoS ONE, 8, e79771.
46. Li, Y., Willer, C.J., Ding, J., Scheet, P. and Abecasis, G.R. (2010) Mach: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet. Epidemiol., 34, 816-834.
47. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J. et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet., 81, 559-575.